Search
Nadroparin Action Pathway
smpdb.ca/view/SMP0126171Drug actionIts mechanism of action after subcutaneous administration causes it to bind to antithrombin III and inactive factor Xa. … The inactivation of factor Xa halted the conversion of prothrombin to thrombin and also halts the conversion of fibrinogen.
Enzymes: Antithrombin-IIITinzaparin Action Pathway
smpdb.ca/view/SMP0126174Drug actionIt binds to antithrombin III forming a complex that speeds up the inhibition of factor Xa. … It can interact with herbs and supplements, so avoid those with anticoagulants and antiplatelet activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo bilba.
Drugs: CalciumEnzymes: Antithrombin-IIISunitinib Action Pathway
smpdb.ca/view/SMP0126868Drug actionSunitinib also affects RET, CSF-1R, and flt3 RTKs. … Sunitinib is a chemotherapeutic agent and receptor tyrosine kinase inhibitor utilized in the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).
Enzymes: Antithrombin-IIIMidostaurin Action Pathway
smpdb.ca/view/SMP0126900Drug actionBy inhibiting these kinases, Midostaurin disrupts signaling cascades that lead to malignancies such as AML and ASM, ultimately inducing apoptosis in leukemia cells and mast cells. … Its mechanism of action involves targeting multiple receptor tyrosine kinases, including protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR, and WT and/or mutant FLT3 tyrosine kinases.
Enzymes: Antithrombin-IIIRegorafenib Action Pathway
smpdb.ca/view/SMP0126907Drug actionRegorafenib functions as an inhibitor of multiple kinases, playing a role in normal cellular processes and pathological conditions like oncogenesis, tumor angiogenesis, and the maintenance of the tumor … Regorafenib is an oral kinase inhibitor with a broad spectrum of activity. It is used to treat metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma.
Enzymes: Antithrombin-IIITivozanib Action Pathway
smpdb.ca/view/SMP0126910Drug actionIn preclinical studies using mice and rats, tivozanib demonstrated its ability to inhibit tumor angiogenesis, slow tumor growth, and reduce vascular permeability. … In the UK and some other countries, it is indicated as the first-line therapy for adults with advanced RCC who have not previously received VEGFR and mTOR pathway inhibitors after their disease has progressed
Enzymes: Antithrombin-IIIHeparin
smpdb.ca/view/SMP0130950PhysiologicalHeparin binds to the enzyme inhibitor antithrombin III (AT), causing a conformational change that results in its activation through an increase in the flexibility of its reactive site loop. … Since heparins depend on the activity of antithrombin, they are considered anticoagulants. Specifically it is also used in the treatment of heart attacks and unstable angina.
Enzymes: Antithrombin-IIICongenital Disorder of Glycosylation CDG-IId
smpdb.ca/view/SMP0000579Diseaseof oligosaccharides and their transfer. … This protein is responsible for the conversion of D-glucose and uridine diphosphategalactose to alpha-lactose and uridine 5’-diphosphate.
Fondaparinux Action Pathway
smpdb.ca/view/SMP0126442Drug actionIt is further potentiated as fondaparinux activates antithrombin III that also inhibits coagulation factor X. … Avoiding herbs and supplements with anticoagulant and antiplatelet activity such as garlic, ginger, ginseng and ginkgo.
Enzymes: Antithrombin-IIICorticosterone Methyl Oxidase II Deficiency (CMO II)
smpdb.ca/view/SMP0000578DiseaseCompared to the CMO-I deficiency, the CMO-II deficiency has less severe mutations in the gene, which cause it to have less severe changes in aldosterone and 18-OHB concentrations. … However, since progesterone and 11b-hydroxyprogesterone are both produced and used by other reactions, their levels in the cell are not changed as drastically.